Hypertension Class Labeling Does Not Release Sponsors From Large Trials
Executive Summary
FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting
You may also be interested in...
Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
Pfizer is petitioning FDA to block expanded indications for Allergan's Lumigan (bimatoprost ophthalmic solution 0.03%) and Alcon's Travatan (travoprost ophthalmic solution 0.004%)
Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
Pfizer is petitioning FDA to block expanded indications for Allergan's Lumigan (bimatoprost ophthalmic solution 0.03%) and Alcon's Travatan (travoprost ophthalmic solution 0.004%)
FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response
Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members